Sputnik-V (Gam-COVID-Vac Lyo) / Gamaleya Research Institute, Dr. Reddy’s - LARVOL DELTA

Assessment of the immune response induced by ChAdOx1 nCoV-19 Oxford-AstraZeneca, Sputnik V, and BNT162b2 Pfizer-BioNTech vaccines during the COVID-19 epidemic outbreak in the Mexican population: Gene expression of the cytokine storm. (PubMed, Infect Genet Evol) - "Longitudinal studies with appropriate controls are needed to establish the biological significance of these transcriptional patterns."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • CD79A • FCGR3A • IL10 • IL2

Implications for future pandemics from a living systematic review and critical evaluation of observational studies of the effectiveness of COVID-19 vaccination against the Omicron variant. (PubMed, Vaccine) - "Reliable evidence on COVID-19 vaccine effectiveness during the period of Omicron variant predominance was essential to inform global vaccination strategies...Weekly searches covering seven databases up to 31 December 2022 sought evidence for WHO-approved vaccine platforms, including mRNA vaccines (BNT162b2, mRNA-1273), adenoviral vector vaccines (ChAdOx1-S, SII-ChAdOx1 nCoV-19, Ad26.COV2·S, Gam-COVID-Vac) and inactivated virus vaccines (CoronaVac, BBV-152)...Most results were judged to be at moderate risk of bias (361, 18%) or at serious risk of bias (1591, 78%) with the principal concern being confounding. We discuss implications for future pandemic preparedness, including the importance of standardized study protocols; robust data linkage between vaccination, testing and outcomes; and validated risk-of-bias frameworks for diverse observational designs."

Journal • Observational data • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Impact of COVID-19 Booster Vaccination on Serum Redox Homeostasis. (PubMed, Int J Mol Sci) - "Prior SARS-CoV-2 infection did not materially alter the qualitative response pattern, whereas older age and comorbidities were associated with greater declines in DPPH activity and albumin. Overall, the findings indicate a modest, transient redox-associated response following booster-induced immune activation and suggest that host-related factors, such as age and comorbidity burden, may accentuate short-term changes in antioxidant buffering capacity."

Biomarker • Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Cellular immune responses 12 months after fractional or standard dose BNT162b2 booster vaccination in Mongolian adults. (PubMed, Front Immunol) - "A total of 601 participants, primed with ChAdOx1-S, BBIBP-CorV, or Gam-COVID-Vac, were randomized (1:1) to receive 15 μg (fractional dose) or 30 μg (standard dose) of BNT162b2...For memory T-cell ICS responses, durability was maintained over 12 months post-vaccination for both wild-type and JN.1 responses. Overall, fractional booster dosing produced comparable and robust long-term humoral and cellular immune responses to a standard dose, including against the JN.1 variant."

Clinical • IO biomarker • Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • CD69 • IFNG • IL2 • TNFA • TNFRSF9

Sputnik V update: safety and neutralizing antibodies in healthy adults and adolescents. (PubMed, Front Immunol) - P3 | "The results of the clinical trials demonstrated a favorable safety profile and a high level of immunogenicity of Sputnik V XBB in adults and adolescents. ClinicalTrials.gov, identifiers NCT06068569 and NCT06068556."

Clinical • Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Fractional BNT162b2 boosters induce durable immune responses after non-mRNA priming in Mongolia: a randomised controlled trial. (PubMed, Front Immunol) - P3 | "In this randomised, controlled trial, adults primed with ChAdOx1-S, BBIBP-CorV, or Gam-COVID-Vac were assigned (1:1) to 15 μg or 30 μg BNT162b2...Equivalent immunity and safety from 15 μg and 30 μg BNT162b2 boosters support fractional dosing as a cost-saving strategy. https://clinicaltrials.gov/study/NCT05265065, identifier NCT05265065."

Clinical • Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • IFNG

COVID-19 vaccine effectiveness against severe acute respiratory infections (SARI) hospitalisations associated with laboratory-confirmed SARS-CoV-2 in Ghana, June 2022 to March 2024. (PubMed, Vaccine) - "COVID-19 vaccines may have prevented COVID-19-associated SARI hospitalizations in the first 6 months over the study period in Ghana, and a pattern of protective effective was observed, consistent with report from other settings, although effect estimates were imprecise."

Journal • Infectious Disease • Influenza • Novel Coronavirus Disease • Respiratory Diseases

Temporal dynamics of SARS-CoV-2 antibodies and IgG subclasses following multiple doses and diverse COVID-19 vaccine combinations. (PubMed, Front Immunol) - "The present study investigated the humoral immune response in 331 participants between January 2021 and January 2023, who received mRNA (BNT162b2-BioNTech/Pfizer, mRNA-1273-Moderna), vector-based (ChAdOx1-S-AstraZeneca, Gam-COVID-Vac-Gamaleya Research Institute), inactivated virus (BBIBP-CorV-Sinopharm) vaccines, or a heterologous combination (ChAdOx1-S followed by mRNA), with all participants receiving an mRNA booster 6-8 months after primary vaccination. The IgG subclass response was more influenced by the type of vaccine used for the two-dose primary vaccination than by the mRNA vaccine used for boosting. Altogether, these findings underscore the importance of booster doses and provide valuable insight into the longevity and quality of humoral responses, including the durability and breadth of neutralizing antibodies, across different vaccination strategies."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

COVID-19 vaccine production and the technological gap in the Global South: The cases of Argentina and Brazil. (PubMed, Vaccine) - "Concurrently, Argentina launched the ARVAC Cecilia Grierson vaccine through a public-private partnership. The persistent technological gap has resulted in continued dependence on foreign imports, undermining their capacity to compete effectively in the international vaccine market. Despite notable achievements in vaccine development and production, the experiences of Argentina and Brazil exemplify the structural difficulties faced by stagnant middle-income nations in achieving vaccine self-sufficiency and technological sovereignty in pharmaceutical manufacturing."

Journal • Infectious Disease • Novel Coronavirus Disease

Sustained superior humoral immune responses of mRNA vaccines compared to Sputnik V viral vector COVID-19 vaccines in naïve and convalescent populations. (PubMed, Vaccine) - "mRNA vaccination provides markedly superior and sustained antibody responses compared to adenoviral vector vaccine, which is particularly relevant for long-term protection strategies."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Autoimmune manifestations recorded after SARS-CoV-2 vaccination. (PubMed, Clin Exp Vaccine Res) - "Nine patients received specific treatments for diagnosed autoimmune diseases (AID), whereas the others showed non-specific immune stimulation, reactive arthritis, myositis, and cerebral venous thrombosis, which improved with symptomatic treatment. This series suggests a link between severe acute respiratory syndrome coronavirus 2 vaccination and triggered or revealed AID or AIM."

Journal • Cardiovascular • Hematological Disorders • Immunology • Infectious Disease • Myositis • Novel Coronavirus Disease • Respiratory Diseases • Rheumatology • Seronegative Spondyloarthropathies • Thrombosis

Neutralization and Anti-S Antibody Titers in SARS-CoV-2 Boosted Adults in Mexico: A Comparison Across Five Vaccine Types. (PubMed, Int J Microbiol) - "We observed that the highest anti-protein S GMTs were in the group that received a heterologous booster with BNT162b2, AZD1222, Ad5-nCoV, or CoronaVac; the group without a booster showed the lowest GMTs...Boosters increased GMTs for all people, independently of their primary vaccine scheme. Yet, our findings suggest that a heterologous booster produced higher titers against SARS-CoV-2 protein S. Efforts should be made to reach people who received AZD1222 and Ad5-nCoV as their primary scheme and did not get boosted, as neutralization in those groups was particularly low."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • PROS1

Immunogenicity and safety at twelve months of fractional and standard BNT162b2 booster doses in adults primed with ChAdOx1-S, BBIBP-CorV, or Gam-COVID-Vac in Mongolia: a randomised controlled trial. (PubMed, Vaccine) - P3 | "15 μg and 30 μg BNT162b2 boosters demonstrated comparable immunogenicity and favourable safety. 15 μg BNT162b2 booster doses may improve vaccine acceptability due to lower reactogenicity."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Immunization route-mediated differences in long-term maturation of humoral immune response induced by adenovirus vector-based COVID-19 vaccine Sputnik V in nonhuman primates. (PubMed, Front Immunol) - "Unlike IN vaccination, IM vaccination also resulted in a continuous long-term increase in serum maturation parameters such as antibody avidity, neutralization potency and breadth. The present study provides valuable information about distinct features of the long-term postvaccination humoral immune response in nonhuman primates induced by adenoviral COVID-19 vaccine administered by the intramuscular and intranasal routes commonly used in clinical practice."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Development and Clinical Validation of a Skin Test for In Vivo Assessment of SARS-CoV-2 Specific T-Cell Immunity. (PubMed, Viruses) - "An integrated clinical analysis included 374 volunteers stratified by vaccination status (EpiVacCorona, Gam-COVID-Vac, CoviVac) prior to COVID-19 infection (Wuhan/Alpha, Delta, Omicron variants), and SARS-CoV-2-naïve controls...047119). Its high safety profile and consistent performance across diverse cohorts support its utility for mass screening and monitoring of cellular immune protection following infection or vaccination."

Journal • Preclinical • Immunology • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • CD4

Neighborhood enrichment for the identification of antigen-specific T-cell receptors. (PubMed, Brief Bioinform) - "While murine datasets provide valuable insights into algorithm performance, caution is advised when extrapolating these results to other species or different experimental conditions. TCRgrapher is freely available on GitHub (https://github.com/KseniaMIPT/tcrgrapher), offering researchers a robust tool for investigating TCR specificity and advancing immunological studies."

Journal • CNS Disorders • Immunology • Infectious Disease • Oncology • Pulmonary Disease • Respiratory Diseases • Tuberculosis

Adverse events of special interest after vaccination with COVID-19 vaccines: a cohort event monitoring study in Iran. (PubMed, Eur J Med Res) - "We found around one AESI among every 8,000 vaccinated Iranian people. The incidence of AESIs after COVID-19 vaccines was relatively rare and the studied vaccines can be considered safe. AZD1222 had a higher incidence of AESIs. Coagulation disorders, and generalized seizure were the main and most common AESIs."

Adverse events • Journal • Cardiovascular • CNS Disorders • Complement-mediated Rare Disorders • Endocrine Disorders • Epilepsy • Hematological Disorders • Infectious Disease • Novel Coronavirus Disease

Evaluation of T cell immune memory response after BBIBP-CorV, gam-COVID-Vac, and heterologous gam-COVID-Vac /mRNA-1273 COVID-19 vaccination schemes against different SARS-CoV-2 variants. (PubMed, Vaccine) - "This study provides new data on effective humoral and cellular immune responses against the ancestral WT virus as well as the Gamma and Omicron variants. Moreover, memory CD4+ and CD8+ T cell responses remain protective, and the heterologous scheme may elicit stronger T cell responses against emerging variants."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • CD4 • CD8

Evaluating miscarriage incidence after COVID-19 vaccination. (PubMed, Sci Rep) - "This cohort study included 26,701 women of reproductive age (15-49) who were vaccinated with different vaccines (Sinopharm, Sputnik V, AZD1222 and CoVIran Barekat) between April 2021 and August 2022 in seven cities in Iran...In general, the miscarriage rate in women of reproductive age was 4.8 (95% CI 4.1-5.7) per 1000 women. The estimated incidence rates were not higher than expected; therefore, it can be argued that COVID - 19 vaccination with Sputnik V, Sinopharm, Barekat and AZD1222 does not increase the probability of miscarriage and the vaccines are therefore safe in this respect."

Journal • Infectious Disease • Novel Coronavirus Disease

FH-63: Phase IIB Study of Recombinant Novel Coronavirus Vaccine (clinicaltrials.gov) - P2 | N=88 | Completed | Sponsor: Fundación Huésped | Active, not recruiting ➔ Completed | Phase classification: P2b ➔ P2 | N=450 ➔ 88

Enrollment change • Phase classification • Trial completion • Infectious Disease • Novel Coronavirus Disease

THE AGE AND TYPE OF THERAPY NEGATIVELY INFLUENCE THE FORMATION OF ANTIBODIES TO SARS-COV-2 VIRUS IN PATIENTS WITH CHRONIC LYMPHOPROLIFERATIVE DISORDERS (CLPD) (EHA 2025) - "33 patients received therapy using monoclonal antibodies (daratumumab - 18; rituximab - 15), chemotherapy - 21, without treatment - 3 subjects... Our study demonstrates that decreased production of Abs to the SARS-CoV-2 virus in patients with CLPD is associated with age and daratumumab use. Daratumumab therapy can lead to rapid depletion of gamma globulins and NK cells. Some studies have shown that approximately 6 months after discontinuation of daratumumab, gamma globulin and NK cell levels recover."

Clinical • Hematological Malignancies • Infectious Disease • Novel Coronavirus Disease • Oncology • Respiratory Diseases

A review of currently licensed mucosal COVID-19 vaccines. (PubMed, Vaccine) - "This highlights the importance of expanded research in this field. In this review, we aim to summarize what is known about these currently licensed vaccines, with an emphasis on the key findings obtained in both preclinical and clinical studies."

Journal • Review • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

The effect of phycocyanins from Arthrospira platensis on the efficacy of immunization with an anti-coronavirus vaccine in vivo (PubMed, Vopr Pitan) - "The manifestation of the Module effects, in contrast to the PC concentrate, is apparently due to its better stability in the gastrointestinal tract environment. Further studies of the secretory activity of immunocompetent cells are needed, which may shed light on the nature of the effect of PC on key parts of the immune system."

Journal • Preclinical • Gastrointestinal Disorder • Hematological Disorders • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

A comparison of Gam-COVID-Vac vaccination and non-vaccination on neurological symptoms and immune response in post-COVID-19 syndrome. (PubMed, Qatar Med J) - "Although certain neurological symptoms may continue, immunization has a beneficial influence on their progression. The results emphasize the crucial role of an increased humoral immune response in individuals with post-COVID-19 syndrome, but do not show significant changes in T-cell immune parameters."

Journal • CNS Disorders • Infectious Disease • Novel Coronavirus Disease • Pain • Sleep Disorder

Triple Rare Thrombosis Including Portal Vein Thrombosis Associated with Vaccine-Induced Immune Thrombotic Thrombocytopenia after Gam-COVID Vac Vaccination (APASL 2025) - "Introduction: The incidence of vaccine-induced immune thrombotic thrombocytopenia (VITT) ranged from 3.2 to 16.1 cases per million after the viral vector vaccines ChAdOx1-S (AstraZeneca, UK) and was 4 times lower after Ad26.COV2.S (Johnson & Johnson, США)...Case description: A 36-year-old woman developed fever above 39.5°C, severe headache, generalized seizure, shortness of breath and abdominal pain 10 days after her first dose of Gam-COVID-Vac (consisting of two recombinant adenovirus vector components, type 26 (rAD26) and type 5 (rAd5), both encoding the S glycoprotein of the SARS-CoV-2 virus (rAD26-S and rAD5-S)...Anticoagulation therapy with rivaroxaban was continued for 6 months until complete resolution of PVT... VITT is a very rare but life-threatening condition characterized by the development of thrombosis, including rare localizations in the setting of thrombocytopenia. In the present case, early diagnosis and early anticoagulant therapy resulted in..."

Anemia • Cardiovascular • CNS Disorders • Complement-mediated Rare Disorders • Epilepsy • Gastroenterology • Genetic Disorders • Hematological Disorders • Hepatology • Immune Thrombocytopenic Purpura • Novel Coronavirus Disease • Pain • Paroxysmal Nocturnal Hemoglobinuria • Pneumonia • Portal Hypertension • Rare Diseases • Respiratory Diseases • Thrombocytopenia • Thrombocytopenic Purpura • Thrombosis • ERCC6